Bactelius Turicea
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bactelius Turicea has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Chloe C. Stinman
Veterinary Diagnostic Laboratory Iowa State University Ames Iowa USA
2 shared publications- Dipak Kumar Sahoo
Department of Veterinary Clinical Sciences, College of Veterinary Medicine, Iowa State University, Ames, IA 50011, USA
2 shared publications - Melissa A. Kubai
Department of Veterinary Clinical Sciences, College of Veterinary Medicine Iowa State University Ames Iowa USA
2 shared publications Christian L. Munevar
Animal Eye Center Inc. Rocklin California USA
1 shared publicationLana L. Linton
Animal Eye Center Inc. Rocklin California USA
1 shared publicationRachel A. Allbaugh
Department of Veterinary Clinical Sciences College of Veterinary Medicine, Iowa State University Ames Iowa USA
1 shared publication
Latest Publications
- Open Access
- 5 October 2025
- Published by Wiley in Veterinary Ophthalmology
- Vol. 29 (2)
Antimicrobial Activity of Ultraviolet C Light as a Potential Novel Treatment for Moraxella bovis Infection—An In Vitro Study
Objective: To investigate the antimicrobial effect of 275 nm wavelength ultraviolet C (UV‐C) light on M. bovis using an affordable, broadly available modified handheld device and to determine if photoreactivation plays a role in bacterial resistance to UV‐C. Methods: UV‐C therapy (UVCT) was evaluated in vitro using triplicates of 3 M. bovis isolates from clinical cases. The UVCT was performed at a distance of 10, 15, and 20 mm with 1 or 2 doses (4 h apart) for 5, 15, or 30 s (s); the photoreactivation plates were exposed to 12 h of light at different times (T): T 0 , T 4 , T 6 , and T 12 after the treatment. Results: In vitro results showed all plates treated with UVCT had a 100% bactericidal effect for all the isolates with a single dose of 15 s at a 10 mm distance. At 15 and 20 mm of distance, 2 doses, 4 h apart, were needed for the same effect, or a single dose of 30 s, which had an 88.8% bactericidal effect. No bacterial regrowth was noticed macroscopically after exposure of the treated plates to artificial light at any time point. Conclusions: The therapeutic potential for killing M. bovis was confirmed in vitro for all tested isolates using a single exposure of 15 s. UVCT can reduce the need for antibiotics, thereby shortening withdrawal periods for animal‐derived food products, having a major impact on the cattle industry. Photoreactivation might not play a role in bacterial resistance to UV‐C. While safety studies are underway, clinical trials are warranted.
- 5 October 2025
- Published by Wiley in Veterinary Ophthalmology
- Vol. 29 (2)
Open AccessAntimicrobial Activity of Ultraviolet C Light as a Potential Novel Treatment for Moraxella bovis Infection—An In Vitro Study
Objective: To investigate the antimicrobial effect of 275 nm wavelength ultraviolet C (UV‐C) light on M. bovis using an affordable, broadly available modified handheld device and to determine if photoreactivation plays a role in bacterial resistance to UV‐C. Methods: UV‐C therapy (UVCT) was evaluated in vitro using triplicates of 3 M. bovis isolates from clinical cases. The UVCT was performed at a distance of 10, 15, and 20 mm with 1 or 2 doses (4 h apart) for 5, 15, or 30 s (s); the photoreactivation plates were exposed to 12 h of light at different times (T): T 0 , T 4 , T 6 , and T 12 after the treatment. Results: In vitro results showed all plates treated with UVCT had a 100% bactericidal effect for all the isolates with a single dose of 15 s at a 10 mm distance. At 15 and 20 mm of distance, 2 doses, 4 h apart, were needed for the same effect, or a single dose of 30 s, which had an 88.8% bactericidal effect. No bacterial regrowth was noticed macroscopically after exposure of the treated plates to artificial light at any time point. Conclusions: The therapeutic potential for killing M. bovis was confirmed in vitro for all tested isolates using a single exposure of 15 s. UVCT can reduce the need for antibiotics, thereby shortening withdrawal periods for animal‐derived food products, having a major impact on the cattle industry. Photoreactivation might not play a role in bacterial resistance to UV‐C. While safety studies are underway, clinical trials are warranted.
- Open Access
- 8 August 2024
- Published by Wiley in Veterinary Ophthalmology
- Vol. 28 (4) , 699-713
Novel treatment of infectious keratitis in canine corneas using ultraviolet C (UV‐C) light
Objective: To investigate the therapeutic effect of 275 nm wavelength ultraviolet C (UV‐C) light for treatment of bacterial keratitis in canine corneas using an affordable, broadly available modified handheld device.Methods: UV‐C therapy (UVCT) was evaluated in two experiments: in vitro using triplicates of three bacterial genera (Staphylococcus, Streptococcus, Pseudomonas spp., and a mix of all species) where the UVCT was performed at a distance of 10, 15, and 20 mm with 1 or 2 doses (4 h apart) for 5, 15, or 30 s; ex vivo model where healthy canine corneal buttons were inoculated superficially and deep (330 μm) with the same bacterial isolates and treated at a 10 mm distance for 15 s with one dose of 22.5 mJ/cm2. Fluorescent marker (STYO9‐PI) was used to label (green = live bacteria, red = dead bacteria), and confocal microscopy was used to image the bacteria.Results: In vitro results showed all plates treated with UVCT had 100% bactericidal effect for all isolates with single dose of 15 s at 10 mm distance or two doses, 4 h apart at 15 mm and was ineffective with single dose at 15–20 mm. The ex vivo results confirmed a significant decrease in bacterial load for all isolates on samples inoculated superficially but were inconclusive for intrastromal ones.Conclusions: UVCT confirmed the therapeutic potential for all tested isolates, for both in vitro and ex vivo experiments using a single exposure of 15 s. While safety studies are underway, clinical trials are warranted.
- 8 August 2024
- Published by Wiley in Veterinary Ophthalmology
- Vol. 28 (4) , 699-713
Open AccessNovel treatment of infectious keratitis in canine corneas using ultraviolet C (UV‐C) light
Objective: To investigate the therapeutic effect of 275 nm wavelength ultraviolet C (UV‐C) light for treatment of bacterial keratitis in canine corneas using an affordable, broadly available modified handheld device.Methods: UV‐C therapy (UVCT) was evaluated in two experiments: in vitro using triplicates of three bacterial genera (Staphylococcus, Streptococcus, Pseudomonas spp., and a mix of all species) where the UVCT was performed at a distance of 10, 15, and 20 mm with 1 or 2 doses (4 h apart) for 5, 15, or 30 s; ex vivo model where healthy canine corneal buttons were inoculated superficially and deep (330 μm) with the same bacterial isolates and treated at a 10 mm distance for 15 s with one dose of 22.5 mJ/cm2. Fluorescent marker (STYO9‐PI) was used to label (green = live bacteria, red = dead bacteria), and confocal microscopy was used to image the bacteria.Results: In vitro results showed all plates treated with UVCT had 100% bactericidal effect for all isolates with single dose of 15 s at 10 mm distance or two doses, 4 h apart at 15 mm and was ineffective with single dose at 15–20 mm. The ex vivo results confirmed a significant decrease in bacterial load for all isolates on samples inoculated superficially but were inconclusive for intrastromal ones.Conclusions: UVCT confirmed the therapeutic potential for all tested isolates, for both in vitro and ex vivo experiments using a single exposure of 15 s. While safety studies are underway, clinical trials are warranted.
- Open Access
- 7 December 2023
- Published by Wiley in Veterinary Ophthalmology
- Vol. 28 (2) , 207-217
Vision outcomes in dogs with primary glaucoma surgically treated with lensectomy and endolaser cyclophotocoagulation after an Ahmed valve gonioimplantation failure
Objective: The aim of this study was to retrospectively evaluate vision outcomes of dogs with primary angle closure glaucoma (PACG) that underwent Ahmed valve gonioimplantation (AVG) followed by lensectomy and endolaser cyclophotocoagulation (ECP) with or without bleb resection after AVG failure.Procedure: Medical records from 2008 to April 2022 were reviewed. All patients selected had an AVG performed first. Following valve failure, lensectomy–ECP was performed in addition to bleb resection as indicated. Additional ECP and AVG replacement surgeries were performed as deemed medically necessary. Main outcomes evaluated included vision preservation, average IOP reduction, and the number of glaucoma medications (both oral and topical) at 6, 12, 24, and 36 months.Results: Fourteen eyes from 13 patients were included in the study. Females were predominant (n = 9) compared with males (n = 4). Mean age at initial glaucoma diagnosis was 6.82 years. Following AVG and lensectomy–ECP, vision was preserved in 93%, 84%, 60%, and 48% of eyes at 1, 2, 3, and 4 years respectively. Following lensectomy–ECP, there was a significant reduction in mean IOP of 9.64 mmHg (p = .015) and 9.71 mmHg (p = .016) at 2 and 6 months, respectively. There was a reduction in mean IOP of 2.45, 7.25, and 12.25 mmHg at 12, 24, and 36 months, respectively, which was not statistically significant. There was a significant decrease in the number of glaucoma medications at all evaluated time points except 24 months.Conclusions: Combined AVG and lensectomy–ECP is successful in maintaining vision long term as well as decreasing IOP, and the number of glaucoma medications administered.
- 7 December 2023
- Published by Wiley in Veterinary Ophthalmology
- Vol. 28 (2) , 207-217
Open AccessVision outcomes in dogs with primary glaucoma surgically treated with lensectomy and endolaser cyclophotocoagulation after an Ahmed valve gonioimplantation failure
Objective: The aim of this study was to retrospectively evaluate vision outcomes of dogs with primary angle closure glaucoma (PACG) that underwent Ahmed valve gonioimplantation (AVG) followed by lensectomy and endolaser cyclophotocoagulation (ECP) with or without bleb resection after AVG failure.Procedure: Medical records from 2008 to April 2022 were reviewed. All patients selected had an AVG performed first. Following valve failure, lensectomy–ECP was performed in addition to bleb resection as indicated. Additional ECP and AVG replacement surgeries were performed as deemed medically necessary. Main outcomes evaluated included vision preservation, average IOP reduction, and the number of glaucoma medications (both oral and topical) at 6, 12, 24, and 36 months.Results: Fourteen eyes from 13 patients were included in the study. Females were predominant (n = 9) compared with males (n = 4). Mean age at initial glaucoma diagnosis was 6.82 years. Following AVG and lensectomy–ECP, vision was preserved in 93%, 84%, 60%, and 48% of eyes at 1, 2, 3, and 4 years respectively. Following lensectomy–ECP, there was a significant reduction in mean IOP of 9.64 mmHg (p = .015) and 9.71 mmHg (p = .016) at 2 and 6 months, respectively. There was a reduction in mean IOP of 2.45, 7.25, and 12.25 mmHg at 12, 24, and 36 months, respectively, which was not statistically significant. There was a significant decrease in the number of glaucoma medications at all evaluated time points except 24 months.Conclusions: Combined AVG and lensectomy–ECP is successful in maintaining vision long term as well as decreasing IOP, and the number of glaucoma medications administered.